The stock of Fate Therapeutics Inc (NASDAQ:FATE) is a huge mover today! The stock decreased 4.85% or $0.15 on November 30, hitting $2.94. About 109,866 shares traded hands. Fate Therapeutics Inc (NASDAQ:FATE) has risen 60.10% since April 27, 2016 and is uptrending. It has outperformed by 54.88% the S&P500.
The move comes after 8 months negative chart setup for the $100.40M company. It was reported on Nov, 30 by Barchart.com. We have $2.70 PT which if reached, will make NASDAQ:FATE worth $8.03 million less.
Analysts await Fate Therapeutics Inc (NASDAQ:FATE) to report earnings on March, 2. They expect $-0.29 EPS, down 11.54% or $0.03 from last year’s $-0.26 per share. After $-0.27 actual EPS reported by Fate Therapeutics Inc for the previous quarter, Wall Street now forecasts 7.41% negative EPS growth.
Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage
Out of 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Fate Therapeutics has been the topic of 6 analyst reports since October 6, 2015 according to StockzIntelligence Inc. On Thursday, September 22 the stock rating was initiated by Roth Capital with “Buy”. The firm earned “Outperform” rating on Tuesday, November 8 by Wedbush. BMO Capital Markets initiated Fate Therapeutics Inc (NASDAQ:FATE) on Tuesday, April 12 with “Outperform” rating. The rating was initiated by TH Capital on Thursday, September 22 with “Buy”. The rating was initiated by Raymond James on Tuesday, October 6 with “Outperform”. The firm earned “Outperform” rating on Friday, December 4 by Wells Fargo.
According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”
Insitutional Activity: The institutional sentiment increased to 0.82 in Q2 2016. Its up 0.26, from 0.56 in 2016Q1. The ratio increased, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.
Nationwide Fund Advisors owns 22,578 shares or 0% of their US portfolio. Allianz Asset Management Ag holds 18,252 shares or 0% of its portfolio. Belmont Global Advsrs reported 400,000 shares or 0.65% of all its holdings. Da Davidson Com last reported 0% of its portfolio in the stock. Natl Bank Of Ny Mellon last reported 0% of its portfolio in the stock. Moreover, State Bank Of America De has 0% invested in Fate Therapeutics Inc (NASDAQ:FATE) for 28,320 shares. Board Of Trustees Of The Leland Stanford Junior University holds 0.07% or 291,067 shares in its portfolio. Moreover, Fmr Limited Com has 0% invested in Fate Therapeutics Inc (NASDAQ:FATE) for 4.31M shares. Goldman Sachs Group holds 35,966 shares or 0% of its portfolio. Franklin Resources holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 500,000 shares. Northern Trust Corporation last reported 25,531 shares in the company. The Kansas-based Creative Planning has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). Blackrock Fund has 75,572 shares for 0% of their US portfolio. Wells Fargo Communications Mn accumulated 1,000 shares or 0% of the stock. Vanguard Group holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 657,573 shares.
Insider Transactions: Since November 23, 2016, the stock had 3 buys, and 0 selling transactions for $1.25 million net activity. Coughlin Timothy P bought 56,390 shares worth $149,997. 375,939 shares were bought by RASTETTER WILLIAM H, worth $999,998. The insider Storgard Chris bought 37,593 shares worth $99,997.
More news for Fate Therapeutics Inc (NASDAQ:FATE) were recently published by: Medgadget.com, which released: “Fate Therapeutics, Inc Clinical Trial Reviews and Clinical Trail Assessment …” on September 14, 2016. 247Wallst.com‘s article titled: “Could This Be a Turning Point for Fate Therapeutics?” and published on June 20, 2016 is yet another important article.
FATE Company Profile
Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.